The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Increased localization of APP ‐C99 in mitochondria‐associated ER membranes causes mitochondrial dysfunction in Alzheimer disease
Open accessAbstract
In the amyloidogenic pathway associated with Alzheimer disease ( AD ), the amyloid precursor protein ( APP ) is cleaved by β‐secretase to generate a 99‐aa C‐terminal fragment (C99) that is then cleaved by γ‐secretase to generate the β‐amyloid (Aβ) found in senile plaques. In previous reports, we and others have shown that γ‐secretase activity is enriched in mitochondria‐associated endoplasmic reticulum ( ER ) membranes ( MAM ) and that ER –mitochondrial connectivity and MAM function are upregulated in AD . We now show that C99, in addition to its localization in endosomes, can also be found in MAM , where it is normally processed rapidly by γ‐secretase. In cell models of AD , however, the concentration of unprocessed C99 increases in MAM regions, resulting in elevated sphingolipid turnover and an altered lipid composition of both MAM and mitochondrial membranes. In turn, this change in mitochondrial membrane composition interferes with the proper assembly and activity of mitochondrial respiratory supercomplexes, thereby likely contributing to the bioenergetic defects characteristic of AD .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“The deleterious effects of A b deposition during the symptomatic stages of AD are undeniable (Hardy & Higgins, 1992), but the role of A b in earlier phases of the disease is still debated.”
Mitofusin 2 tethers endoplasmic reticulum to mitochondria
de Brito, O. M., & Scorrano, L. (2008) · Nature · doi:10.1038/nature07534 · Cited by 2,442 · cited 1×
“To assess apposition, we transfected control and PS-DKO cells with markers of ER and mitochondria, and measured their colocalization (de Brito & Scorrano, 2008; Area-Gomez et al , 2012) in the absence or presence of BI to prevent the generation of C99; remarkably, incubation with BI rescued the…”
Manczak, M., Anekonda, T. S., Henson, E., Park, B. S., Quinn, J., & Reddy, P. H. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl066 · Cited by 1,104 · cited 2×
“This last conclusion disagrees with proposals that the accumulation of A b 42 oligomers in mitochondria triggers the mitochondrial defects seen in AD (Manczak et al , 2006).”
Trafficking and Proteolytic Processing of APP
Haass, C., Kaether, C., Thinakaran, G., & Sisodia, S. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006270 · Cited by 1,075 · cited 1×
“Many reports have shown that C99 is localized mainly in endosomes (Haass et al , 2012; Das et al , 2016).”
Luo, Y., Bolon, B., Kahn, S., Bennett, B. D., Babu-Khan, S., Denis, P., Fan, W., Kha, H., Zhang, J., Gong, Y., et al. (2001) · Nature Neuroscience · doi:10.1038/85059 · Cited by 1,001
Yao, J., Irwin, R. W., Zhao, L., Nilsen, J., Hamilton, R. T., & Brinton, R. D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903563106 · Cited by 940 · cited 2×
“Finally, our results linking C99, rather than higher levels of A b 42 , to mitochondrial dysfunction help explain how mitochondrial alterations can occur early in AD pathogenesis (Balietti et al , 2013), preceding the appearance of A b -containing plaques (Yao et al , 2009).”
Respiratory active mitochondrial supercomplexes
Acín-Pérez, R., Fernández-Silva, P., Peleato, M. L., Pérez-Martos, A., & Enriquez, J. A. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.10.021 · Cited by 817
Self-citationThe Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives
Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.010 · Cited by 786 · cited 2×
“Among these, perturbed mitochondrial function, including reduced respiratory chain activity and ATP production, and increased oxidative stress (Du et al , 2010), have been described extensively (Swerdlow et al , 2014), occurring before the appearance of plaques (Yao et al , 2009; Wang et al , 2014).”
Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease
Yang, L.-B., Lindholm, K., Yan, R., Citron, M., Xia, W., Yang, X.-L., Beach, T., Sue, L., Wong, P., Price, D., et al. (2003) · Nature Medicine · doi:10.1038/nm0103-3 · Cited by 729
Upregulated function of mitochondria‐associated ER membranes in Alzheimer disease
Area‐Gomez, E., del Carmen Lara Castillo, M., Tambini, M. D., Guardia‐Laguarta, C., de Groof, A. J. C., Madra, M., Ikenouchi, J., Umeda, M., Bird, T. D., Sturley, S. L., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.202 · Cited by 638 · cited 8×
“…that is increased in AD is the synthesis of PtdSer by phosphatidylserine synthases 1 and 2 (PTDSS1/2) (Vance, 2014; Kannan et al , 2017 #2382, Wu & Voelker, 2004; Area-Gomez et al , 2012 #234), resulting in higher levels of this phospholipid in MAM and other membranes in AD cells and tissues.”
InfluentialSelf-citation
Cited by
Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: Recent advances.
Wang, W., Zhao, F., Ma, X., Perry, G., & Zhu, X. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00376-6 · Cited by 1,274
Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future
Zhang, Y., Chen, H., Li, R., Sterling, K., & Song, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01484-7 · Cited by 988
“C99, a C-terminal fragment of APP cleaved by β-secretase, also activated sphingolipid turnover and increased ceramide to impact the ERmitochondria contacts, leading to impaired mitochondrial respiration and metabolic disturbance.(212) Mitochondria are also the major source of oxidative stress because the inevitable le…”
BackgroundYin, F. (2023) · The FEBS Journal · doi:10.1111/febs.16344 · Cited by 441
Vaillant-Beuchot, L., Mary, A., Pardossi-Piquard, R., Bourgeois, A., Lauritzen, I., Eysert, F., Kinoshita, P. F., Cazareth, J., Badot, C., Fragaki, K., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-020-02234-7 · Cited by 263
Mitochondria and Calcium in Alzheimer’s Disease: From Cell Signaling to Neuronal Cell Death
Calvo-Rodriguez, M., & Bacskai, B. J. (2021) · Trends in Neurosciences · doi:10.1016/j.tins.2020.10.004 · Cited by 254
Mitophagy in Alzheimer’s disease: Molecular defects and therapeutic approaches
Mary, A., Eysert, F., Checler, F., & Chami, M. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01631-6 · Cited by 244
A key role for MAM in mediating mitochondrial dysfunction in Alzheimer disease
Area-Gomez, E., de Groof, A., Bonilla, E., Montesinos, J., Tanji, K., Boldogh, I., Pon, L., & Schon, E. A. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0215-0 · Cited by 235
Self-citationVance, J. E. (2018) · Journal of Lipid Research · doi:10.1194/jlr.r084004 · Cited by 113
Deciphering the Roles of Metformin in Alzheimer’s Disease: A Snapshot
Liao, W., Xu, J., Li, B., Ruan, Y., Li, T., & Liu, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.728315 · Cited by 84
Bhattacharyya, R., Black, S. E., Lotlikar, M. S., Fenn, R. H., Jorfi, M., Kovacs, D. M., & Tanzi, R. E. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109134 · Cited by 84
Cao, Y., Zhao, L.-W., Chen, Z.-X., & Li, S.-H. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1430465 · Cited by 65
Area-Gomez, E., Larrea, D., Pera, M., Agrawal, R. R., Guilfoyle, D. N., Pirhaji, L., Shannon, K., Arain, H. A., Ashok, A., Chen, Q., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-61142-8 · Cited by 55
Self-citationMitochondrial function and Aβ in Alzheimer's disease postmortem brain
Troutwine, B. R., Strope, T. A., Franczak, E., Lysaker, C. R., Hamid, L., Mansel, C., Stopperan, J. A., Gouvion, C. M., Haeri, M., Swerdlow, R. H., et al. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105781 · Cited by 51
Amyloid precursor protein‐mediated mitochondrial regulation and Alzheimer's disease
Lopez Sanchez, M. I. G., van Wijngaarden, P., & Trounce, I. A. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14554 · Cited by 45
MH84 improves mitochondrial dysfunction in a mouse model of early Alzheimer’s disease
Pohland, M., Pellowska, M., Asseburg, H., Hagl, S., Reutzel, M., Joppe, A., Berressem, D., Eckert, S. H., Wurglics, M., Schubert‐Zsilavecz, M., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0342-6 · Cited by 33
Li, Z., Cao, Y., Pei, H., Ma, L., Yang, Y., & Li, H. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1158204 · Cited by 30
Contribution of Mitochondrial DNA Variation to Chronic Disease in East Asian Populations
Sun, D., Wei, Y., Zheng, H.-X., Jin, L., & Wang, J. (2019) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2019.00128 · Cited by 21
“…fusion (Levine and Kroemer, 2008). mtDNA mutation can lead to mitophagy (Dombi et al., 2016) and mitochondrial dysfunction (Dolle et al., 2016; Pera et al., 2017; Ehrnhoefer et al., 2018; Lindqvist et al., 2018; Pereira et al., 2018; Puthumana and Regenold, 2019) have long been reported as…”
BackgroundGarcía‐González, L., Paumier, J., Louis, L., Pilat, D., Bernard, A., Stephan, D., Jullien, N., Checler, F., Nivet, E., Khrestchatisky, M., et al. (2021) · The FASEB Journal · doi:10.1096/fj.202100593r · Cited by 16
Metadata
- Authors
- Pera, M., Larrea, D., Guardia‐Laguarta, C., Montesinos, J., Velasco, K. R., Agrawal, R. R., Xu, Y., Chan, R. B., Di Paolo, G., Mehler, M. F., Perumal, G. S., Macaluso, F. P., Freyberg, Z. Z., Acin‐Perez, R., Enriquez, J. A., Schon, E. A., & Area‐Gomez, E.
- Venue
- The EMBO Journal
- Published
- 2017-10-10
- Volume
- 36
- Issue
- 22
- Pages
- 3356-3371
- ISSN
- 0261-4189 (ISSN-L)
- 1460-2075
- OpenAlex
- W2760938608
- Cited by
- 234
- References
- 19
- FWCI
- 10.82
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.